Surrozen, Inc. Common Stock (SRZN) Stock
NASDAQ · SRZN
29.15
Fundamentals
Market cap
$347.20M
Price / Earnings ratio
-1.2x
Price / Sales ratio
34.4x
Price / Book ratio
-1.8x
Return on assets
-329.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
NeutralSRZNSeptember 25, 2026
StocktwitsNeutral
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
SRZN

24/7 Wall Street
Huge Insider Buying in Media by Warren Buffet and More
NeutralSRZNApril 14, 2024
24/7 Wall StreetNeutral
Huge Insider Buying in Media by Warren Buffet and More
SRZN

Zacks Investment Research
5 Top Stocks Likely to Come Up With Earnings Beat
NeutralSRZNApril 13, 2023
Zacks Investment ResearchNeutral
5 Top Stocks Likely to Come Up With Earnings Beat
SRZN

PennyStocks
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
NeutralSRZNFebruary 9, 2023
PennyStocksNeutral
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
SRZN
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 4 articles
published over the past 14 days
Latest news

Stocktwits
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
NeutralSRZNSeptember 25, 2026
StocktwitsNeutral
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
SRZN

24/7 Wall Street
Huge Insider Buying in Media by Warren Buffet and More
NeutralSRZNApril 14, 2024
24/7 Wall StreetNeutral
Huge Insider Buying in Media by Warren Buffet and More
SRZN

Zacks Investment Research
5 Top Stocks Likely to Come Up With Earnings Beat
NeutralSRZNApril 13, 2023
Zacks Investment ResearchNeutral
5 Top Stocks Likely to Come Up With Earnings Beat
SRZN

PennyStocks
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
NeutralSRZNFebruary 9, 2023
PennyStocksNeutral
Penny Stocks To Buy? 4 Cheap Stocks To Watch Right Now
SRZN
About Surrozen, Inc. Common Stock
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
SectorHealthcare
IndustryBiotechnology
Employees44
CEOMr. Craig C. Parker M.B.A.
IPO DateJan 11, 2021
HeadquartersSouth San Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig C. Parker M.B.A. | CEO, President & Director | 1962 |
| Mr. Charles Williams | COO & Corporate Secretary | 1980 |
| Dr. Yang Li Ph.D. | Executive Vice President of Research | 1969 |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board | — |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1950 |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor | — |
| Mr. Andrew Maleki | Chief Financial Officer | 1990 |
| Dr. Daniel L. Chao M.D., Ph.D. | VP & Head of Clinical Development | — |
| Mr. Michael Lauw M.S.W. | Senior Vice President of Development Operations | — |
| Esther Jhun | Controller | — |
Fundamentals
Valuation
Market cap$347.20M
Price-to-sales ratio34.39
Price-to-book value-1.81
Price-earnings ratio-1.20
Return on Equity310.00%
Return on Sales-4571.00%
Return on Assets-329.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-41.14
Income Statement
Average volume700,294
EBITDA$-340.45M
1 year high (52w)$35.86
1 year low (52w)$11.39
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Buy12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$54.00
Est return
81.21%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +78.7 |



